K. Phillips

Combined catheter ablation for atrial fibrillation and Watchman® left atrial appendage occlusion procedures: Five-year experience

Patients with atrial fibrillation (AF) may benefit from undergoing concomitant interventions of left atrial catheter ablation and device occlusion of the left atrial appendage (LAA) as a two‐pronged strategy for rhythm control and stroke prevention. We report on the outcome of combined procedures in a single center case series over a 5‐year timeframe.

Left atrial catheter ablation subsequent to Watchman® left atrial appendage device implantation: a single centre experience.

AIMS Left atrial appendage device occlusion is an increasingly accepted therapy for stroke prevention in atrial fibrillation. The feasibility and safety of left atrial catheter ablation procedures in the presence of a left atrial appendage device implant is unclear. We report on 10 cases of successful left atrial catheter ablation therapy for atrial fibrillation in patients with an implanted Watchman® device. METHODS AND RESULTS Consecutive patients with an existing Watchman® left atrial appendage implant and symptomatic antiarrhythmic-drug refractory atrial fibrillation or atrial tachycardias requiring left atrial catheter ablation therapy were included. Open irrigated tip ablation and circular mapping catheters were positioned in the left atrium via double transseptal access. Ten patients underwent successful left atrial geometry creation and complex atrial arrhythmia mapping and ablation in the presence of a chronically implanted Watchman® device. Arrhythmia targets included left atrial flutters, a focal tachycardia, left atrial CFAE zones, and pulmonary vein electrical isolation. The appearances of the Watchman® device position and device integrity were confirmed to be satisfactory in all patients at the end of the procedure based on fluoroscopy and intracardiac echocardiography imaging. There were no procedural complications. CONCLUSION Left atrial catheter ablation therapy in the presence of an implanted Watchman® left atrial appendage occlusion device was efficacious and uncomplicated in our small single centre experience.

Combining Watchman left atrial appendage closure and catheter ablation for atrial fibrillation: multicentre registry results of feasibility and safety during implant and 30 days follow-up

Abstract Aims Long-term results from catheter ablation therapy for atrial fibrillation (AF) remain uncertain and clinical practice guidelines recommend continuation of long-term oral anticoagulation in patients with a high stroke risk. Left atrial appendage closure (LAAC) with Watchman has emerged as an alternative to long-term anticoagulation for patients accepting of the procedural risks. We report on the initial results of combining catheter ablation procedures for AF and LAAC in a multicentre registry. Methods and results Data were pooled from two prospective, real-world Watchman LAAC registries running in parallel in Europe/Middle-East/Russia (EWOLUTION) and Asia/Australia (WASP) between 2013 and 2015. Of the 1140 patients, 139 subjects at 10 centres underwent a concomitant AF ablation and LAAC procedure. The mean CHA2DS2-VASc score was 3.4 ± 1.4 and HAS-BLED score 1.5 ± 0.9. Successful Watchman implantation was achieved in 100% of patients. The overall 30-day serious adverse event (SAE) rate was 8.7%, with the device and/or procedure-related SAE rate of 1.4%. One pericardial effusion required percutaneous drainage, but there were no strokes, device embolization, or deaths at 30 days. The 30-day bleeding SAE rate was 2.9% with 55% of patients prescribed NOAC and 38% taking warfarin post-procedure. Conclusion The outcomes from these international, multicentre registries support the feasibility and safety of performing combined procedures of ablation and Watchman LAAC for patients with non-valvular AF and high stroke risk. Further data are needed on long-term outcomes for the hybrid technique on all-cause stroke and mortality.

Long term outcomes from catheter ablation of very longstanding persistent atrial fibrillation

INTRODUCTION Success rates for catheter ablation of longstanding persistent atrial fibrillation (AF) are significantly poorer than for recently persistent or paroxysmal forms. We report on single centre long term outcomes from ablation of very longstanding (> 2years) persistent AF. MATERIAL AND METHODS A retrospective analysis of outcomes for patients undergoing catheter ablation for symptomatic very longstanding persistent AF between 2008 and 2013 was performed. RESULTS Twenty-nine patients were followed for a mean of 61±15months following the index ablation procedure. The mean duration of persistent AF prior was 64±51months (range 24-200), mean age 61±6years and mean CHA2DS2-VASc score 1.1±1.2. Antral pulmonary vein electrical isolation only was performed in 14 (48%) with the remainder having additional lines and/or CFAE ablation also. At last follow-up 24 (83%) were in sinus rhythm but only 9 (31%) remained free of detectable arrhythmia, 25 (86%) were taking antiarrhythmic therapy and 18 (62%) required intermittent DC cardioversions. The mean time to first AF recurrence was 14±14months (range 2-48). Redo ablation was required in 13 (45%) at a mean follow-up time of 15±12months. The mean EHRA score improved from 3.5±0.5 to 1.4±0.4 (p<0.0001). CONCLUSIONS The vast majority (83%) of very longstanding persistent AF patients maintained sinus rhythm at a mean follow-up time of 5years following catheter ablation, associated with a significant improvement in symptom scores. Adjunctive therapies including antiarrhythmics, DC cardioversions and redo ablation were required in most patients.

Dealing With the Left Atrial Appendage for Stroke Prevention: Devices and Decision-Making

Left atrial appendage (LAA) device occlusion represents a major evolution in stroke prevention for atrial fibrillation (AF). Left atrial appendage device occlusion is now a proven strategy which provides long-term thromboembolic stroke prevention for patients with non-rheumatic AF. Evidence supports its benefit as an alternative to long-term anticoagulation while mitigating long-term bleeding risks and improving cardiovascular mortality. The therapy offers expanded options to physicians and patients negotiating stroke prevention (both primary and secondary prevention), but a good understanding of the risks and benefits is required for decision-making. This review aims to summarise the evolution of LAA device occlusion therapy, current knowledge in the field and a snapshot of current status of the therapy in clinical practice in Australia and around the world.

Double transseptal puncture adjacent to multiple Amplatzer atrial septal occluders: case report.

Successful transseptal puncture adjacent to a single Amplatzer atrial septal closure device is well described. Rarely multiple Amplatzer devices may be required to close defects in the interatrial septum. We report on successful double transseptal puncture adjacent to multiple Amplatzer atrial septal occluder devices for the purposes of catheter ablation for atrial fibrillation.

Combined atrial fibrillation ablation and left atrial appendage closure: long-term follow-up from a large multicentre registry

Aims Long-term freedom from atrial fibrillation (AF) after catheter ablation (CA) and consequently the potential for stroke reduction remain unpredictable. Percutaneous left atrial appendage closure (LAAC) is an effective mechanical alternative to oral anticoagulation (OAC) for stroke prevention in AF patients. This study aims to evaluate long-term clinical results of combined CA and LAAC in one single procedure. Methods and results Patients with non-valvular AF who underwent combined CA and LAAC procedure were included in the retrospective compilation of independent prospective general LAAC registries at the individual centres. Transoesophageal echocardiography (TOE) was used to evaluate device position and LAA sealing. Between 2009 and 2015, 349 patients with AF (58% male, age 63.1 ± 8.2 years; score for stroke prediction in AF patients (CHA2DS2-VASc) 3.0; score for major bleeding in patients on anticoagulation (HAS-BLED) 3.0; 56% paroxysmal AF) were included. Indications for LAAC included previous stroke (38%), history of bleeding (22%), and physician/patient preference (29%). Periprocedural complications up to 30 days included pericardial effusion (1.5%) and one minor stroke (0.3%) but no death. After 6 weeks, TOE showed successful sealing of the LAA in 98.9%. After 35 months of follow-up, 51% of patients had AF recurrence. A total of nine ischaemic strokes were recorded, resulting in an annualized stroke rate of 0.9% compared to an expected stroke rate of 3.2% without anticoagulation and combined treatment. Conclusion This large pooled multicentre analysis of five prospective registries shows that combining CA and LAAC is feasible, safe, and successful. Long-term follow-up shows greatly reduced stroke and bleeding rates despite recurrence of AF in more than half of the patients.

Atrial Fibrillation and Stroke Epidemiology

Atrial fibrillation is a common cardiovascular disorder strongly associated with ischaemic stroke and is an independent predictor of all-cause mortality. AF-related stroke is associated with increased stroke severity, poorer survival, greater disability among survivors and a higher recurrence rate of stroke as compared with other etiologies. The costs associated with stroke-related healthcare are higher for AF than non-AF subjects. However, AF-related stroke is largely preventable. The incidence and prevalence of AF increases substantially with age. Further, a global trend in rising prevalence of AF has been demonstrated in recent decades. The epidemiology of atrial fibrillation and AF-related stroke is reviewed in detail in this chapter.